Application

SB 202190 may be used to inhibit p38-mediated cell signaling.

SB 202190 monohydrochloride hydrate has been used as a component of human prostate culture medium and organoid culture medium It has also been used as p38 mitogen activated protein kinase (MAPK) inhibitor in colon cancer cells.

Biochem/physiol Actions

SB 202190 is a highly selective, potent, and cell-permeable inhibitor of p38 MAP kinase.

SB 202190 monohydrochloride hydrate mediates the phosphorylation of serine in the mutant p53 protein and modulates cell adhesion and prevents cell proliferation in breast cancer cell lines.

SB 202190 binds within the ATP pocket of p38 kinase and inhibits the p38α and β isoforms.

Features and Benefits

This compound is featured on the MAPKs page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

5, 25 mg in glass bottle